On May 6, 2020 Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, reported that interim phase I clinical data from the phase I/II trial evaluating systemic durvalumab + intraperitoneal ONCOS-102 in patients with peritoneal disease originating from ovarian or colorectal cancer, will be presented at the ASCO (Free ASCO Whitepaper)20 Virtual Scientific conference, 29-31 May 2020 (Press release, Targovax, MAY 6, 2020, View Source [SID1234557182]). The trial is a collaboration with Cancer Research Institute (CRI) and Ludwig Cancer Research (Ludwig, trial sponsor) and AstraZeneca.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract will be released on 13 May on View Source

Abstract title:

Phase I/II study to evaluate systemic durvalumab + intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results.

Abstract no.:

3017

Presenter:

Dmitriy Zamarin, MD, PhD